Article Text

Lessons from ECLIPSE: a review of COPD biomarkers
Free
  1. Rosa Faner1,
  2. Ruth Tal-Singer2,
  3. John H Riley3,
  4. Bartolomé Celli4,
  5. Jørgen Vestbo5,6,
  6. William MacNee7,
  7. Per Bakke8,
  8. Peter M A Calverley9,
  9. Harvey Coxson10,
  10. Courtney Crim11,
  11. Lisa D Edwards11,
  12. Nick Locantore11,
  13. David A Lomas12,
  14. Bruce E Miller2,
  15. Stephen I Rennard13,
  16. Emiel F M Wouters14,
  17. Julie C Yates11,
  18. Edwin K Silverman4,
  19. Alvar Agusti1,15 on behalf of the ECLIPSE Study Investigators
  1. 1Fundació Investigació Sanitària Illes Balears (FISIB), Ciber Enfermedades Respiratorias (CIBERES), Barcelona, Catalunya, Spain
  2. 2GlaxoSmithKline Research and Development, King of Prussia, Pennsylvania, USA
  3. 3GlaxoSmithKline Research and Development, Stevenage, UK
  4. 4Channing Division of Network Medicine and Pulmonary and Critical Care Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
  5. 5Department of Respiratory Medicine, Odense University Hospital, and Clinical Institute, University of Southern Denmark, Odense, Denmark
  6. 6Respiratory and Allergy Research Group, Manchester Academic Health Sciences Centre, University Hospital South Manchester NHS Foundation Trust, Manchester, UK
  7. 7University of Edinburgh, MRC Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh, UK
  8. 8Department of Thoracic Medicine, Institute of Clinical Science, University of Bergen, Haukeland University Hospital, Bergen, Norway
  9. 9Division of Infection and Immunity Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
  10. 10Department of Radiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
  11. 11GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, USA
  12. 12Division of Medicine, University College London, London, UK
  13. 13Department of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
  14. 14Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
  15. 15Thorax Institute, Hospital Clinic, IDIBAPS, Univ. Barcelona, Barcelona, Spain
  1. Correspondence to Dr Alvar Agustí, Institut del Tòrax, Hospital Clínic, Villarroel 170, Escala 3, Planta 5, Barcelona 08036, Spain; alvar.agusti{at}clinic.ub.es

Abstract

The Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study was a large 3-year observational controlled multicentre international study aimed at defining clinically relevant subtypes of chronic obstructive pulmonary disease (COPD) and identifying novel biomarkers and genetic factors. So far, the ECLIPSE study has produced more than 50 original publications and 75 communications to international meetings, many of which have significantly influenced our understanding of COPD. However, because there is not one paper reporting the biomarker results of the ECLIPSE study that may serve as a reference for practising clinicians, researchers and healthcare providers from academia, industry and government agencies interested in COPD, we decided to write a review summarising the main biomarker findings in ECLIPSE.

  • Emphysema

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.